NCT01306591

Bevacizumab for Neovascular Age-related Macular Degeneration

Randomized Multi-center Clinical Study：Bevacizumab for Neovascular Age-related Macular Degeneration

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 210 (actual)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: 50 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.

Conditions

• Exudative Age-related Macular Degeneration

Interventions

Type	Name	Description
DRUG	Bevacizumab 1	Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
DRUG	Bevacizumab	Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week

Timeline

• Start date: 2008-01-01
• Primary completion: 2010-06-01
• Completion: 2010-12-01
• First posted: 2011-03-02
• Last updated: 2011-03-02

Locations

1 site across 1 country: China